登录 +0086-27-65522453 [email protected]

Dactolisib (BEZ235, NVP-BEZ235) 编号 : 52619

化学信息

产品英文名称Dactolisib (BEZ235, NVP-BEZ235)
同义词Dactolisib, BEZ235, NVP-BEZ235,NVPBEZ235
英文同义词Dactolisib, BEZ235, NVP-BEZ235,NVPBEZ235
分子式C30H23N5O 
分子量469.54 
SmileCC(C)(C#N)n1c2c3cc(ccc3ncc2n(c1=O)C)c4cc5ccccc5nc4
InChiKeyKGAAOKXUCALAPY-UHFFFAOYSA-N
InChiInChI=1S/C24H19N5O/c1-24(2,14-25)29-22-18-11-15(17-10-16-6-4-5-7-19(16)26-12-17)8-9-20(18)27-13-21(22)28(3)23(29)30/h4-13H,1-3H3
Cas915019-65-7
MDLMFCD18785767

技术数据

外观固体粉末
纯度98% 
可溶性可溶于DMSO;不溶于水
存储短期可在0-4度保存,数天至数月;长期可在-20度保存三年。
运输条件可在常温下运输
质量控制

产品详情

From Wikipedia, the free encyclopedia

Dactolisib (codenamed NVP-BEZ235 and BEZ-235) is an imidazoquinoline derivative acting as a PI3K inhibitor.[1] It also inhibits mTOR. It is being investigated as a possible cancer treatment.

It has been shown to be toxic to Waldenström's macroglobulinemia cells.

It was the first PI3K inhibitor to enter clinical trials, in 2006.

A phase IB/II clinical trial for locally advanced or metastatic HER2 negative breast cancer has completed.

A phase II clinical trial for advanced pancreatic neuroendocrine tumors (pNET) has reported results.

结构

52619 - Dactolisib (BEZ235, NVP-BEZ235) | CAS 915019-65-7

包装

规格价格
登录 to get price

快速订购

Change

联系我们